Total Payments
$40,510
2024 Payments
$17,948
Companies
12
Transactions
32
Medicare Patients
573
Medicare Billing
$93,994
Payment Breakdown by Category
Consulting$33,530 (82.8%)
Other$3,595 (8.9%)
Travel$2,611 (6.4%)
Food & Beverage$768.41 (1.9%)
Education$5.42 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $33,530 | 9 | 82.8% |
| Travel and Lodging | $2,611 | 6 | 6.4% |
| Honoraria | $1,914 | 2 | 4.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,572 | 2 | 3.9% |
| Food and Beverage | $768.41 | 11 | 1.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $108.50 | 1 | 0.3% |
| Education | $5.42 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | $21,108 | 11 | $0 (2024) |
| GENZYME CORPORATION | $12,824 | 10 | $0 (2024) |
| Genentech USA, Inc. | $2,080 | 1 | $0 (2022) |
| Blueprint Medicines Corporation | $1,898 | 2 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,500 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $675.00 | 1 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $150.00 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $108.50 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $72.34 | 1 | $0 (2021) |
| Sobi, Inc | $70.20 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,948 | 13 | GENZYME CORPORATION ($10,522) |
| 2023 | $14,986 | 8 | Apellis Pharmaceuticals, Inc. ($12,544) |
| 2022 | $5,726 | 6 | Apellis Pharmaceuticals, Inc. ($3,576) |
| 2021 | $1,681 | 3 | Merck Sharp & Dohme LLC ($1,500) |
| 2019 | $150.00 | 1 | Alexion Pharmaceuticals, Inc. ($150.00) |
| 2017 | $18.32 | 1 | Spectrum Pharmaceuticals Inc. ($18.32) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/16/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: Immunology | ||||||
| 04/01/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Travel and Lodging | Cash or cash equivalent | $892.08 | General |
| Category: Hematology | ||||||
| 03/20/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Consulting Fee | Cash or cash equivalent | $4,095.00 | General |
| Category: Hematology | ||||||
| 02/17/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $9,226.00 | General |
| 02/17/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $381.41 | General |
| 02/17/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $296.21 | General |
| 02/17/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $280.34 | General |
| 02/17/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $139.06 | General |
| 02/17/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $77.39 | General |
| 02/17/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $46.43 | General |
| 02/17/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $38.66 | General |
| 02/17/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $36.23 | General |
| 01/03/2024 | Blueprint Medicines Corporation | — | Honoraria | Cash or cash equivalent | $1,764.00 | General |
| 12/10/2023 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $21.33 | General |
| Category: Hematology | ||||||
| 10/13/2023 | Apellis Pharmaceuticals, Inc. | EMPAVELI (Drug) | Consulting Fee | Cash or cash equivalent | $7,780.50 | General |
| Category: Hematology | ||||||
| 10/13/2023 | Apellis Pharmaceuticals, Inc. | EMPAVELI (Drug) | Travel and Lodging | Cash or cash equivalent | $647.55 | General |
| Category: Hematology | ||||||
| 08/23/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Education | Cash or cash equivalent | $5.42 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 06/16/2023 | Apellis Pharmaceuticals, Inc. | EMPAVELI (Drug) | Consulting Fee | Cash or cash equivalent | $1,638.00 | General |
| Category: Hematology | ||||||
| 06/13/2023 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $134.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 04/25/2023 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,302.50 | General |
| 03/17/2023 | Apellis Pharmaceuticals, Inc. | EMPAVELI (Drug) | Consulting Fee | Cash or cash equivalent | $2,457.00 | General |
| Category: Hematology | ||||||
| 12/09/2022 | Apellis Pharmaceuticals, Inc. | EMPAVELI (Drug) | Travel and Lodging | Cash or cash equivalent | $113.31 | General |
| Category: Hematology | ||||||
| 12/02/2022 | Apellis Pharmaceuticals, Inc. | EMPAVELI (Drug) | Consulting Fee | Cash or cash equivalent | $3,276.00 | General |
| Category: Hematology | ||||||
| 11/17/2022 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $101.37 | General |
| Category: Hematology | ||||||
| 10/27/2022 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,080.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 124 | 240 | $50,422 | $21,523 |
| 2022 | 4 | 174 | 324 | $67,639 | $31,460 |
| 2021 | 3 | 136 | 227 | $42,711 | $21,738 |
| 2020 | 4 | 139 | 248 | $49,522 | $19,272 |
Total Patients
573
Total Services
1,039
Medicare Billing
$93,994
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 28 | 75 | $17,819 | $7,788 | 43.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 77 | $13,765 | $6,059 | 44.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 29 | 63 | $11,210 | $4,583 | 40.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $3,808 | $1,614 | 42.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $3,820 | $1,480 | 38.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 53 | 126 | $28,592 | $14,034 | 49.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 21 | 47 | $10,663 | $5,207 | 48.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 33 | 65 | $10,976 | $4,873 | 44.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 40 | 58 | $9,807 | $4,255 | 43.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $5,213 | $2,119 | 40.6% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 11 | 12 | $2,388 | $972.94 | 40.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 41 | 94 | $14,562 | $7,329 | 50.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 24 | 40 | $8,610 | $4,537 | 52.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 20 | 31 | $6,725 | $3,601 | 53.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 32 | 43 | $6,639 | $3,401 | 51.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 19 | 19 | $6,175 | $2,869 | 46.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 38 | 92 | $19,780 | $7,734 | 39.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 60 | 115 | $17,692 | $7,065 | 39.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 24 | 24 | $7,800 | $2,860 | 36.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 17 | 17 | $4,250 | $1,613 | 38.0% |
About Dr. Timothy Kubal, MD
Dr. Timothy Kubal, MD is a Hematology & Oncology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2007. The National Provider Identifier (NPI) number assigned to this provider is 1982808689.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Timothy Kubal, MD has received a total of $40,510 in payments from pharmaceutical and medical device companies, with $17,948 received in 2024. These payments were reported across 32 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($33,530).
As a Medicare-enrolled provider, Kubal has provided services to 573 Medicare beneficiaries, totaling 1,039 services with total Medicare billing of $93,994. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Tampa, FL
- Active Since 06/14/2007
- Last Updated 10/14/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1982808689
Products in Payments
- EMPAVELI (Drug) $15,912
- Empaveli (Drug) $5,195
- Fabhalta (Drug) $675.00
- Soliris (Drug) $150.00
- AYVAKIT (Drug) $134.00
- DOPTELET (Drug) $70.20
- Folotyn (Drug) $18.32
- Rezlidhia (Drug) $5.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tampa
Damian Laber, Md, MD
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Eduardo Sotomayor, Md, MD
Hematology & Oncology — Payments: $447,992
Hematology & Oncology $447,992
Ariel Grajales-Cruz
Hematology & Oncology — Payments: $424,303
Hematology & Oncology $424,303
Dr. Kendra Sweet, M.d, M.D
Hematology & Oncology — Payments: $215,309
Hematology & Oncology $215,309
Khaldoun Almhanna, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $173,538
Hematology & Oncology $173,538
Hayder Saeed, M.d, M.D
Hematology & Oncology — Payments: $140,365
Hematology & Oncology $140,365